American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
In August 2022, these guidelines were reviewed by an expert work group convened by ASH.
Review included limited searches for new evidence and discussion of the search results …
Review included limited searches for new evidence and discussion of the search results …
[HTML][HTML] Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism …
T Van der Hulle, J Kooiman, PL Den Exter… - Journal of Thrombosis …, 2014 - Elsevier
Introduction New direct oral anticoagulants (NOACs) constitute a novel treatment option for
acute venous thromboembolism (VTE), with practical advantages. Individual studies have …
acute venous thromboembolism (VTE), with practical advantages. Individual studies have …
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
KAA Fox, JP Piccini, D Wojdyla, RC Becker… - European heart …, 2011 - academic.oup.com
Aims Patients with non-valvular atrial fibrillation (AF) and renal insufficiency are at increased
risk for ischaemic stroke and bleeding during anticoagulation. Rivaroxaban, an oral, direct …
risk for ischaemic stroke and bleeding during anticoagulation. Rivaroxaban, an oral, direct …
New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis
IL Holster, VE Valkhoff, EJ Kuipers, ETTL Tjwa - Gastroenterology, 2013 - Elsevier
BACKGROUND & AIMS: A new generation of oral anticoagulants (nOAC), which includes
thrombin and factor Xa inhibitors, has been shown to be effective, but little is known about …
thrombin and factor Xa inhibitors, has been shown to be effective, but little is known about …
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation
New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been
developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients …
developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients …
Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism …
Background—Evidence regarding the use of direct oral anticoagulants (DOACs) in the
elderly, particularly bleeding risks, is unclear despite the presence of greater comorbidities …
elderly, particularly bleeding risks, is unclear despite the presence of greater comorbidities …
Direct oral anticoagulants in patients with VTE and cancer
BACKGROUND Direct oral anticoagulants (DOAs) have been shown to be as effective and
at least as safe as conventional anticoagulation for the prevention of recurrences in patients …
at least as safe as conventional anticoagulation for the prevention of recurrences in patients …
Apixaban, an oral, direct factor X a inhibitor: Single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
C Frost, J Wang, S Nepal, A Schuster… - British Journal of …, 2013 - Wiley Online Library
Aims To evaluate apixaban single dose safety, tolerability, pharmacokinetics and
pharmacodynamics and assess the effect of food on apixaban pharmacokinetics. Methods A …
pharmacodynamics and assess the effect of food on apixaban pharmacokinetics. Methods A …
Apixaban metabolism and pharmacokinetics after oral administration to humans
N Raghavan, CE Frost, Z Yu, K He, H Zhang… - Drug metabolism and …, 2009 - ASPET
The metabolism and disposition of [14C] apixaban, an orally bioavailable, highly selective,
and direct acting/reversible factor Xa inhibitor, was investigated in 10 healthy male subjects …
and direct acting/reversible factor Xa inhibitor, was investigated in 10 healthy male subjects …
[HTML][HTML] Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous …
Background Anticoagulation with low molecular weight heparin and vitamin K antagonists is
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …